Inhalierbare Kortikosteroide in der Langzeittherapie der COPD

 

 Permissions and Reprints

Einleitung

Die COPD (Chronic Obstructive Pulmonary Disease) ist charakterisiert durch eine strukturelle und funktionell vorwiegend exspiratorisch wirksame Behinderung des Atemflusses, deren Ausmaß sich innerhalb einer Beobachtungszeit von einigen Monaten nicht spontan bessert. Die Atemwegsobstruktion ist in der Regel progredient, im Gegensatz zum Asthma bronchiale wenig variabel und nach inhalativer Gabe eines kurzwirksamen β₂-Agonisten kaum reversibel (FEV₁-Verbesserung < 10 %) [[1], [2]]. Folgende Symptome können bei diesem Krankheitsbild auftreten: chronischer Husten, Auswurf und Atemnot vor allem bei körperlicher Belastung und bei Infekten [[3]]. Weitere funktionelle Charakteristika dieser Erkrankung sind eine Überblähung der Lunge und eine Reduktion der Diffusionskapazität [[3] [4] [5]].

Literatur

• 1 American Thoracic Society . Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 1995;  152 S77-S120
  PubMedGoogle Scholar
• 2 Barnes P, Godfrey S. Chronic obstructive pulmonary disease. London: Martin Dunitz 1997
  Google Scholar
• 3 Petty T L, Weinmann G G. Building a national strategy for the prevention and management of and research in chronic obstructive pulmonary disease.  JAMA. 1997;  277 246-253
  CrossrefPubMedGoogle Scholar
• 4 British Thoracic Society . Guidelines for the management of chronic obstructive pulmonary disease.  Thorax. 1997;  52 S1-S28
  CrossrefPubMedGoogle Scholar
• 5 Fabbri L M, Caramori G, Beghe B, Papi A, Ciaccia A. Chronic obstructive pulmonary disease international guidelines.  Curr Opin Pulm Med. 1998;  4 76-84
  PubMedGoogle Scholar
• 6 Fletcher C, Peto R. The natural history of chronic airway obstruction.  Br Med J. 1977;  1 1645-1648
  CrossrefPubMedGoogle Scholar
• 7 Jeffery P K. Morphology of the airway wall in asthma and in chronic obstructive pulmonary disease.  Am Rev Respir Dis. 1991;  143 1152-1158
  PubMedGoogle Scholar
• 8 Jeffery P K. Comparative morphology of the airways in asthma and chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 1994;  150 S6-S13
  PubMedGoogle Scholar
• 9 Oxman A, Muir D CF, Shannon H S, Stock S R, Hnizdo E, Lange H J. Occupational dust exposure and chronic obstructive pulmonary disease.  Am Rev Respir Dis. 1993;  148 38-48
  CrossrefPubMedGoogle Scholar
• 10 Senior R M, Shapiro D. Chronic obstructive pulmonary disease: epidemiology, pathophysiology, and pathogenesis. In: Fishman AP, Elias JA, Fishman JA, Grippi MA, Kaiser LR, Senior RM (Hrsg.). Fishman's pulmonary diseases and disorders New York: McGraw-Hill 1998: 659-681
  Google Scholar
• 11 Canadian Thoracic Society Workshop Group . Guidelines for the assessment and management of chronic obstructive pulmonary disease.  Can Med Assoc J. 1992;  147 420-428
  PubMedGoogle Scholar
• 12 Schäfer H, Ewig S, Gillissen A. Therapie der schweren Exazerbation bei chronisch obstruktiver Lungenerkrankung (COPD). Intensivmed. 2000b im Druck
  Google Scholar
• 13 Siafakas N M, Vermeire P, Pride N B, Paoletti P, Gibson J, Howard P, Yernault J C, Decramer M, Higenbottam T, Postma D S, Rees J. Optimal assessment and management of chronic obstructive pulmonary disease (COPD).  Eur Respir J. 1995;  8 1398-1420
  CrossrefPubMedGoogle Scholar
• 14 Wettengel R, Böhning W, Cegla U, Criée C, Fichter J, Geisler L, Fabel H, Köhler D, Konietzko N, Lindemann H, Magnussen H, Matthys H, Meister R, Morr H, Nolte D, Petro W, Schultze-Werninghaus G, Sill V, Sybrecht G W, Wiesner B, Worth H. Empfehlungen der Deutschen Atemwegsliga zur Behandlung von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem.  Med Klinik. 1995;  90 3-7
  PubMedGoogle Scholar
• 15 Jackevicius C, Joyce D P, Kesten S, Chapman K R. Prehospitalization inhaled corticosteroid use in patients with COPD or asthma.  Chest. 1997;  111 296-302
  PubMedGoogle Scholar
• 16 Kardos P. Differentialdiagnose Asthma - COPD. Münch Med Wschr 2000 im Druck
  Google Scholar
• 17 Lepage T, Bourcereau J, Terrioux P, Velicitat P, Roche N. Influence des résultats du test de réversibilité de l'obstruction bronchique sur la prise en charge de bronchopneumopathies chroniques obstructives (BPCO) en pratique pneumologique.  Rev Mal Respir. 2000;  17 S25
  PubMedGoogle Scholar
• 18 Barnes J P. Inhaled Corticosteroids are not beneficial in chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2000;  161 342-344
  PubMedGoogle Scholar
• 19 Calverley P MA. Inhaled Corticosteroids are beneficial in chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 2000;  161 341-344
  CrossrefPubMedGoogle Scholar
• 20 Gillissen A. Kortisontherapie bei chronisch-obstruktiver Bronchitis - Contra-Position.  Dtsch Med Wschr. 2000;  125 222-223
  Article in Thieme ConnectPubMedGoogle Scholar
• 21 Schäfer H, Ewig S, Gillissen A. Therapeutische Optionen im Management der stabilen chronisch obstruktiven Lungenerkrankung (COPD). Dtsch Med Wschr 2000a im Druck
  Google Scholar
• 22 Vogelmeier C. Kortisontherapie bei chronisch-obstruktiver Bronchitis - Pro-Position.  Dtsch Med Wschr. 2000;  125 220-221
  Article in Thieme ConnectPubMedGoogle Scholar
• 23 Vestbo J, Sørensen T, Langer P, Brix A, Torre A, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial.  Lancet. 1999;  355 1819-1823
  PubMedGoogle Scholar
• 24 Pauwels R A, Lofdahl C G, Laitinen L A, Schouten J P, Postma D S, Pride N B, Ohlsson S V. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking.  N Engl J Med. 1999;  340 1948-1953
  CrossrefPubMedGoogle Scholar
• 25 Paggiaro P L, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease.  Lancet. 1998;  351 773-780
  CrossrefPubMedGoogle Scholar
• 26 Burge P S, Calverley P M, Jones P W, Spencer S, Anderson J A, Maslen T K. Randomised, double blind, placebo-controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease; The ISOLDE trial.  BMJ. 2000;  320 1297-1303
  CrossrefPubMedGoogle Scholar
• 27 Anthonisen N R, Connett J E, Kiley J P, Altose M D, Bailey W C, Buist A S, Conway Jr W A, Enright P L, Kanner R E, O'Hara P. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study.  JAMA. 1994;  272 1539-1541
  CrossrefPubMedGoogle Scholar
• 28 Barnes P J. New therapies for chronic obstructive pulmonary disease.  Thorax. 1998;  53 137-147
  PubMedGoogle Scholar
• 29 McEvoy C E, Niewoehner D E. Adverse effects of corticosteroid therapy for COPD. A critical review.  Chest. 1997;  111 732-743
  PubMedGoogle Scholar
• 30 Renkema T EJ, Schouten J P, Koeter G H, Postma D S. Effects of long-term treatment with corticosteroids in COPD.  Chest. 1996;  109 1156-1162
  PubMedGoogle Scholar
• 31 Bourbeau J, Rouleau M Y, Boucher S. Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease.  Thorax. 1998;  53 477-482
  PubMedGoogle Scholar
• 32 Cox G, Whitehead L, Dolovich M, Jordana M, Gauldie J, Newhouse M T. A randomized controlled trial on the effect of inhaled corticosteroids on airways inflammation in adult cigarette smokers.  Chest. 1999;  115 1271-1277
  CrossrefPubMedGoogle Scholar
• 33 Fujimoto K, Kubo K, Yamamoto H, Yamaguchi S, Matsuzawa Y. Eosinophilic inflammation in the airway is related to glucocorticoid reversibility in patients with pulmonary emphysema.  Chest. 1999;  115 697-702
  CrossrefPubMedGoogle Scholar
• 34 Confalonieri M, Mainardi E, Della Porta R, Bernorio S, Gandola L, Beghé B, Spanevello A. Inhaled corticosteroide reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease.  Thorax. 1998;  53 583-585
  PubMedGoogle Scholar
• 35 Keatings V M, Jatakanon A, Worsdell Y M, Barnes P J. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD.  Am J Respir Crit Care Med. 1997;  155 542-548
  PubMedGoogle Scholar
• 36 Llewellyn-Jones C G, Harris T A, Stockley R A. Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema.  Am J Respir Crit Care Med. 1996;  153 616-621
  PubMedGoogle Scholar
• 37 Efthimiou J, Barnes P J. Effect of inhaled corticosteroids on bones and growth.  Eur Respir J. 1998;  11 707-709
  PubMedGoogle Scholar
• 38 Goldstein M F, Fallon Jr J J, Harning R. Chronic glucocorticoid therapy-induced osteoporosis in patients with obstructive lung disease.  Chest. 1999;  116 1733-1749
  CrossrefPubMedGoogle Scholar
• 39 Calverley P MA. Re-assessing the evidence about inhaled corticosteroids in chronic obstructive pulmonary disease.  Thorax. 1999;  54 3-4
  PubMedGoogle Scholar
• 40 Pizzichini E, Pizzichini M MM, Gibson P, Parameswaran K, Gleich G J, Berman P, Dolovich J, Hargreave F E. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis.  Am J Respir Crit Care Med. 1998;  158 1511-1517
  CrossrefPubMedGoogle Scholar
• 41 Dompeling E, van Schayck C P, van Grunsven P M, van Herwaarden C LA, Akkermans R P, Molema J, Folgering H, van Weel C. Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids.  Ann Intern Med. 1993;  118 770-778
  PubMedGoogle Scholar
• 42 Prescott E, Langer P, Vestbo J. Socioeconomic status, lung function and admission to hospital for COPD: results from the Copenhagen City Heart Study.  Eur Respir J. 1999;  13 1109-1114
  CrossrefPubMedGoogle Scholar
• 43 Niewoehner D E, Erbland M L, Deupree R H, Collins D, Gross N J, Light R W, Anderson P, Morgan N A. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease.  N Engl J Med. 1999;  340 1941-1947
  CrossrefPubMedGoogle Scholar

Prof. Dr A Gillissen

Med. Universitätsklinik und Poliklinik II

Sigmund-Freud-Str. 25 53105 Bonn

Email: E-mail: adrian.gillissen@mailer.meb.uni-bonn.de